Dr. John Cush RheumNow
5 years 11 months ago
QD Clinics - Vignette Lessons from Rheum Clinic. Week 2: choosing IL-1 inhibitors, burnt out RA or not RA, trigger fingers, peripheral SpA, Gout or not? Listen on iTunes https://t.co/FHJv01Sb3a or on Android https://t.co/V488PY9lIo
American College of Rheumatology ACRheum
5 years 11 months ago
Congratulations to Carlos J. Lozada, MD, recipient of the 2020 Distinguished Fellowship Program Director Award! @UMiamiHealth #ACR20 https://t.co/OsiChNSbjn
Victoria Shanmugam VickiShanmugam
5 years 11 months ago
Looking forward to Cool Comedy Hot Cuisine with @bobsaget tomorrow evening - supporting #scleroderma research. This year the event is online - join us wherever you are! @srfcure https://t.co/2iuRKOKk3J
Peter Nash drpnash
5 years 11 months ago
(Ethic)Efficacy of tocilizumab in patients with hand osteoarthritis: double blind, randomised, placebo-controlled, multicentre trial https://t.co/7k7p6HJ4Ni #tocilizumab #OAhands another one bites the dust!
Dr. John Cush RheumNow
5 years 11 months ago
SELECT CHOICE, H2H study of UPA vs ABA in TNF-IR RA pts; UPA had better DAS28-CRP & ABA had better Safety outcomes; Which would you use?
Prospective observational findings from the CORRONA registry of rheumatoid arthritis (RA) patients compared clinical outcomes between initial aggressive therapy using either a tumour necrosis factor inhibitor (TNFi) or a non-TNFi (biological disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs)) and found no difference between these diverse biologically targeted therapies.
Dr. John Cush RheumNow
5 years 11 months ago
QD Clinics - Vignette Lessons from Rheum Clinic - Compilation on No Shows, Delays in SpA Dx, & when patients bail out on DMARD therapy. Listen on iTunes https://t.co/FHJv01AAbC on on Android> https://t.co/i8icH8AS9m
Dr. John Cush RheumNow
5 years 11 months ago
Pre Print of UK research suggests biomarkers for Severe COVID-19 includes markers of myeloid or endothelial activation; such as D-dimer, EN-RAGE, CXCL10, GM-CSF, IL-6, TNF-α, IL-2, GDF-15, G-CSF, S100A12, https://t.co/Yv6yM4DYmp
The U.S. Food and Drug Administration announced today in a Drug Safety Communication that it is requiring labeling changes for nonsteroidal anti-inflammatory drugs (NSAIDs).
Dr. John Cush RheumNow
5 years 11 months ago
259 SLE patients followed an 80% were in lupus low disease activity state (LLDAS); 82% in remission; 19% w/ active dz. 56 pst in subjective Low activity (SLQ<6) compared to SLAQ>6, latter had more arthritis, fibromyalgia and took steroids https://t.co/IdeSNlaEOG
QD97 - Gout Goes Chronic
Thinking about acute gout that evolves to chronic
Dr. Jack Cush sings the news and journal reports from the past week on RheumNow.com.
QD Clinic - Dx & Rx of Peripheral Spondyloarthritis
QD Clinic - Lessons from the clinic
How B/L Oligo synovitis can be SpA and how to treat it.
Features Dr. Jack Cush
Dr. John Cush RheumNow
5 years 11 months ago
Juvenile localized scleroderma was Rx w/ MTX or MMF (in MTX refractory) and compared retrospectively. Facial linear scler. more likely in MTX pts and MMF pts had pansclerotic morphea or mixed subtype. Outcomes were same at 9.4 yrs: inactive in 100% & 91% https://t.co/2X9SpqeLwx
